CT-SCAN DETERMINATION OF ADVANCED, HETEROGENEOUS UPPER LOBE EMPHYSEMA AT SITES PARTICIPATING IN A MULTICENTER TRIAL OF THE INTRABRONCHIAL VALVE DO NOT REQUIRE A CENTRAL CORE LAB FOR CONFIRMATION

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 325S
Author(s):  
David Ost ◽  
Justin P. Smith ◽  
Xavier Gonzalez ◽  
Steven C. Springmeyer ◽  
Robert McKenna
1998 ◽  
Vol 44 (12) ◽  
pp. 2530-2536 ◽  
Author(s):  
Huub E van Ingen ◽  
Daniel W Chan ◽  
Walter Hubl ◽  
Hayato Miyachi ◽  
Rafael Molina ◽  
...  

Abstract The CA 125 II assay on the Elecsys® 2010 analyzer was evaluated in an international multicenter trial. Imprecision studies yielded within-run CVs of 0.8–3.3% and between-day CVs of 2.4–10.9%; CVs for total imprecision in the manufacturer’s laboratory were 2.4–7.8%. The linear range of the assay extended to at least 4500 kilounits/L (three decades). Interference from triglycerides (10.3 mmol/L), bilirubin (850 μmol/L), hemoglobin (1.1 mmol/L), anticoagulants (plasma), and several widely used drugs was undetectable. Method comparisons with five other CA 125 II assays showed good correlation but differences in standardization. A 95th percentile cutoff value of 35 kilounits/L was calculated from values measured in 593 apparently healthy (pre- and postmenopausal) women. In 95% of patients with benign gynecological diseases CA 125 was ≤190 kilounits/L; 63% of patients with newly diagnosed ovarian carcinoma had values >190 kilounits/L. A comparison of CA 125 values obtained with the Elecsys test and with other common CA 125 tests in monitored patients being treated for ovarian cancer showed identical patterns. In conclusion, the Elecsys CA 125 II assay is linear over a broad range, yields precise and accurate results, is free from interferences, and compares well with other assays.


2020 ◽  
Vol 9 (1) ◽  
pp. 85-89
Author(s):  
MY Dofe ◽  
◽  
KS Nemade ◽  
NY kamadi ◽  
◽  
...  

1996 ◽  
Vol 110 (7) ◽  
pp. 673-675 ◽  
Author(s):  
B. J. Conlon ◽  
A. Curran ◽  
C. V. Timon

AbstractWe present two cases of suppurative sinusitis that presented to our casualty department over a one-week period. Both patients suffered complications of the disease secondary to extension of the inflammatory process beyond the bony confines of the sinus. Neither of the patients had a previous history of sinus disease. The first patient deteriorated suddenly 24 hours after admission. The initial computed tomography (CT) scan failed to demonstrate a developing subdural empyema. This complication was confirmed following repeat scanning 24 hours later and the patient required urgent neurosurgical intervention and drainage. The second patient presented with periorbital cellulitis secondary to sinusitis and suffered a grand mal seziure on admission. Once again initial CT scan changes were subtle and significant intracranial extension was not noted until the subsequent magnetic resonance imaging (MRI) scan was performed.The purpose of this paper is to highlight the potential dangers over reliance on CT scanning in diagnosing early intracranial spread of sinus disease and we emphasise that the clinician must interpret any radiological investigations in light of the associated clinical findings.


2012 ◽  
Vol 48 ◽  
pp. S180-S181 ◽  
Author(s):  
M.B. van den Assem ◽  
J. Visser ◽  
H.M. Zonderland ◽  
G. van Tienhoven ◽  
K.F. Crama ◽  
...  

2008 ◽  
Vol 63 (11) ◽  
pp. 687-689
Author(s):  
E Wiberg-Itzel ◽  
C Lipponer ◽  
M Norman ◽  
A Herbst ◽  
D Prebensen ◽  
...  

2013 ◽  
pp. n/a-n/a
Author(s):  
Núria Vizcaíno Revés ◽  
Cristina Stahl ◽  
Michael Stoffel ◽  
Monty Bali ◽  
Franck Forterre
Keyword(s):  
Ct Scan ◽  

1995 ◽  
Vol 5 (9) ◽  
pp. 1684-1688
Author(s):  
G L Bakris ◽  
U Starke ◽  
M Heifets ◽  
D Polack ◽  
M Smith ◽  
...  

Prostaglandins of the E series (PGE) are known to contribute to the maintenance of renal hemodynamics in subjects with chronic renal insufficiency. Agents that block PGE synthesis, nonsteroidal anti-inflammatory agents (NSAID), are widely used by people with renal insufficiency. This study was undertaken in subjects with renal insufficiency secondary to diabetes to evaluate the acute effects of a PGE1 analog, misoprostol, on NSAID-induced changes in RBF, as calculated by para-aminohippurate clearance, and GFR, as calculated by inulin clearance. Sodium excretion was also assessed. Twenty-five fasting subjects with a mean age of 56 +/- 4 yr received 800 mg of ibuprofen orally. A concomitant dose of either a placebo (PL) or 200 micrograms of misoprostol was also given. This was followed in 1 h by either a placebo or an additional 200-micrograms dose of misoprostol. Measurements for the determination of RBF, GFR, blood pressure, and fractional excretion of sodium were performed every 30 min for the next 5 h. The greatest reduction in both GFR (-25 +/- 7 mL/min per 1.73 m2 PL versus -10 +/- 4 mL/min per 1.73 m2, misoprostol delta GFR; P < 0.05) and RBF (-48 +/- 21 mL/min per 1.73 m2 PL versus -15 +/- 8 mL/min per 1.73 m2, M delta RBF; P < 0.05) occurred approximately 2 h after the NSAID dose. No significant differences were noted in blood pressure, fractional excretion of sodium, or other measured parameters between groups during the entire study. Gastrointestinal upset was the most common side effect observed in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)


Sign in / Sign up

Export Citation Format

Share Document